U.S. Human Leukocyte Antigen (HLA) Typing Transplant Diagnostics Services Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

U.S. Human Leukocyte Antigen (HLA) Typing Transplant Diagnostics Services Market Size

• The U.S. Human Leukocyte Antigen (HLA) Typing Transplant Diagnostics Services Market size was valued at USD 1.64 billion in 2025 and is expected to reach USD 3.64 billion by 2033, at a CAGR of 10.50% during the forecast period
• The market growth is largely fueled by the increasing demand for organ and stem cell transplantation, along with continuous advancements in molecular diagnostic technologies, leading to improved accuracy and efficiency in donor–recipient compatibility testing across hospitals and transplant centers
• Furthermore, rising awareness regarding the importance of precise immunogenetic testing, growing investments in transplant diagnostics infrastructure, and increasing adoption of advanced laboratory testing services are establishing Human Leukocyte Antigen (HLA) Typing Transplant Diagnostics Services as essential components of modern transplant medicine. These converging factors are accelerating the uptake of Human Leukocyte Antigen (HLA) Typing Transplant Diagnostics Services solutions, thereby significantly boosting the industry's growth

U.S. Human Leukocyte Antigen (HLA) Typing Transplant Diagnostics Services Market Analysis

• Human Leukocyte Antigen (HLA) typing transplant diagnostics services, offering advanced immunogenetic testing to determine donor–recipient compatibility, are increasingly vital components of modern transplant medicine across hospitals, transplant centers, and diagnostic laboratories due to their ability to improve transplant success rates and reduce the risk of graft rejection
• The escalating demand for Human Leukocyte Antigen (HLA) Typing Transplant Diagnostics Services is primarily fueled by the increasing number of organ and stem cell transplants, growing awareness of precision transplant diagnostics, and rising adoption of advanced molecular typing technologies such as next-generation sequencing and PCR-based assays
• U.S. experiencing substantial growth in HLA typing diagnostic services across hospitals, transplant centers, and specialized laboratories due to increasing organ transplant programs and adoption of high-throughput molecular typing technologies
• The Diagnostics segment dominated the largest market revenue share of 63.5% in 2025, driven by the increasing number of organ and tissue transplantation procedures worldwide

Report Scope and U.S. Human Leukocyte Antigen (HLA) Typing Transplant Diagnostics Services Market Segmentation   

U.S. Human Leukocyte Antigen (HLA) Typing Transplant Diagnostics Services Market Trends

“Increasing Adoption of Advanced Molecular Typing Technologies”

• A significant and accelerating trend in the global U.S. Human Leukocyte Antigen (HLA) Typing Transplant Diagnostics Services Market is the growing adoption of advanced molecular diagnostic technologies that improve the accuracy and reliability of donor–recipient matching in organ and stem cell transplantation
• Healthcare providers and transplant laboratories are increasingly shifting from traditional serological typing methods to advanced molecular techniques such as next-generation sequencing (NGS) and polymerase chain reaction (PCR)-based typing, which provide higher resolution results and reduce the risk of transplant rejection
• For instance, in 2025 several leading transplant centers in the U.S. and Europe expanded the use of next-generation sequencing (NGS)-based HLA typing platforms, enabling clinicians to achieve more precise donor compatibility assessments for bone marrow and kidney transplants. Similarly, major diagnostic laboratories in Japan and Germany have integrated high-throughput molecular typing systems to improve turnaround time and enhance transplant success rates
• Continuous advancements in molecular diagnostics are improving the efficiency and scalability of HLA typing services. Modern HLA typing platforms now support high-resolution genotyping, automated workflows, and improved data interpretation, allowing laboratories to process large volumes of transplant compatibility tests with higher precision and reduced manual intervention
• The increasing collaboration between transplant centers, diagnostic laboratories, and biotechnology companies is also accelerating the development of innovative HLA typing solutions. These collaborations are enabling healthcare providers to expand access to advanced transplant diagnostics and improve patient outcomes globally
• Furthermore, the growing demand for personalized medicine and precision diagnostics is encouraging healthcare institutions to adopt advanced HLA typing services that support better clinical decision-making and improved transplant compatibility evaluation
• As the number of organ and hematopoietic stem cell transplant procedures continues to increase globally, the demand for reliable and high-resolution HLA typing diagnostic services is expected to grow significantly across hospitals, research laboratories, and transplant registries

U.S. Human Leukocyte Antigen (HLA) Typing Transplant Diagnostics Services Market Dynamics

Driver

“Rising Number of Organ and Stem Cell Transplant Procedures Worldwide”

• The increasing number of organ and hematopoietic stem cell transplant procedures across the globe is a major driver fueling the demand for HLA typing transplant diagnostic services. Accurate HLA matching between donors and recipients is essential for minimizing transplant rejection risks and improving long-term graft survival rates, making HLA typing a critical step in the transplantation process
• For instance, according to global transplant registries, kidney and bone marrow transplant procedures have increased significantly in countries such as the United States, Germany, China, and India, leading to a higher demand for reliable HLA typing services to ensure precise donor compatibility. Major transplant hospitals and diagnostic laboratories are expanding their HLA typing capabilities to accommodate the growing volume of transplant cases
• In addition, the increasing prevalence of chronic diseases such as kidney failure, leukemia, lymphoma, and other immune-related disorders is contributing to the rising demand for organ and stem cell transplantation procedures. As a result, healthcare providers are relying more heavily on advanced HLA typing services to ensure successful transplant outcomes
• Government initiatives promoting organ donation awareness and the expansion of donor registries are also supporting the growth of the HLA typing transplant diagnostics services market. Several countries have launched national transplant programs aimed at improving donor matching systems and increasing transplant success rates
• Furthermore, the expansion of specialized transplant centers and diagnostic laboratories across developed and emerging economies is improving patient access to advanced HLA typing services, thereby driving overall market growth

 Restraint/Challenge

“High Cost of Advanced Testing Technologies and Limited Laboratory Infrastructure”

• Despite the growing importance of HLA typing in transplantation medicine, the high cost associated with advanced molecular testing technologies remains a significant challenge for many healthcare systems, particularly in developing regions. High-resolution sequencing platforms, specialized reagents, and laboratory automation systems require substantial investment, which can limit the widespread adoption of advanced HLA typing services
• For instance, several hospitals and diagnostic laboratories in parts of Africa, Southeast Asia, and Latin America still rely on conventional HLA typing techniques due to limited access to advanced sequencing technologies and specialized laboratory infrastructure, which can affect the speed and precision of donor-recipient matching
• Another challenge is the shortage of highly trained laboratory professionals capable of performing complex molecular HLA typing procedures and interpreting high-resolution genetic data. Skilled personnel are essential for maintaining diagnostic accuracy and ensuring reliable transplant compatibility testing
• In addition, regulatory requirements and quality assurance standards for transplant diagnostics can increase operational complexity for laboratories. Diagnostic service providers must comply with strict accreditation standards and maintain high levels of testing accuracy, which may increase operational costs and slow the expansion of new diagnostic facilities
• Addressing these challenges through investments in laboratory infrastructure, development of cost-effective testing solutions, and training programs for laboratory professionals will be essential for expanding access to HLA typing transplant diagnostic services and ensuring continued market growth globally

U.S. Human Leukocyte Antigen (HLA) Typing Transplant Diagnostics Services Market Scope

The market is segmented on the basis of technology, product and services, application, and end-use.

• By Technology

On the basis of technology, the U.S. Human Leukocyte Antigen (HLA) Typing Transplant Diagnostics Services Market is segmented into Non-Molecular Assays and Molecular Assays. The Molecular Assays segment dominated the largest market revenue share of 58.4% in 2025, driven by the increasing adoption of highly accurate DNA-based typing techniques in transplantation diagnostics. Molecular assays such as PCR-based typing and next-generation sequencing provide high resolution and precise identification of HLA alleles, which is critical for successful organ and stem cell transplantation. Hospitals and transplant laboratories increasingly prefer molecular assays due to their superior sensitivity and reliability compared to conventional serological methods. The rising number of organ transplant procedures worldwide is significantly boosting the demand for advanced molecular diagnostics. Technological advancements and automation in sequencing platforms are further improving testing efficiency and turnaround time. Additionally, increased government funding for transplant programs and research initiatives is supporting segment growth. The expansion of transplant registries and donor matching programs globally is also contributing to strong adoption.

The Non-Molecular Assays segment is expected to witness the fastest CAGR of 9.7% from 2026 to 2033, fueled by the growing demand for cost-effective HLA typing solutions in developing healthcare markets. Non-molecular assays remain widely used for preliminary screening due to their relatively simple procedures and affordability. Diagnostic laboratories in emerging economies continue to rely on serological typing techniques where advanced molecular infrastructure may not be fully available. Increasing awareness regarding organ donation and transplantation programs is also expanding the demand for accessible diagnostic solutions. Healthcare institutions are adopting non-molecular methods as complementary tools alongside molecular technologies. Furthermore, continuous improvements in assay sensitivity and workflow efficiency are enhancing their clinical utility. Government initiatives promoting affordable diagnostic services are also supporting adoption. The expansion of hospital diagnostic laboratories across developing regions is expected to accelerate the growth of this segment during the forecast period.

• By Product and Services

On the basis of product and services, the market is segmented into Instruments, Reagents and Consumables, Software, and Services. The Reagents and Consumables segment dominated the largest market revenue share of 49.1% in 2025, driven by the recurring demand for reagents used in HLA typing assays and transplant compatibility testing. Reagents are essential components in molecular and serological typing procedures, leading to continuous procurement by diagnostic laboratories and hospitals. Increasing transplant procedures and rising adoption of advanced molecular typing technologies are further boosting demand. Laboratories frequently require new reagent kits and consumables for each test cycle, generating consistent revenue streams in the market. Additionally, innovations in reagent formulations are improving assay sensitivity and accuracy. Expansion of transplant registries and diagnostic laboratories is also contributing to increased reagent consumption. Strategic collaborations between diagnostic companies and healthcare institutions are supporting widespread adoption.

The Services segment is expected to witness the fastest CAGR of 11.2% from 2026 to 2033, driven by the growing outsourcing of HLA typing and transplant compatibility testing to specialized diagnostic service providers. Hospitals and research institutions increasingly rely on external laboratories to conduct complex genetic testing due to cost and infrastructure considerations. Service providers offer advanced technologies, skilled professionals, and rapid testing capabilities that improve transplant success rates. Rising demand for donor-recipient matching services and stem cell registry testing is accelerating service adoption. Furthermore, expansion of transplant networks and international donor registries is increasing the need for high-quality diagnostic services. Continuous technological advancements and improved laboratory workflows are also supporting market growth in this segment.

• By Application

On the basis of application, the U.S. Human Leukocyte Antigen (HLA) Typing Transplant Diagnostics Services Market is segmented into Diagnostics and Research. The Diagnostics segment dominated the largest market revenue share of 63.5% in 2025, driven by the increasing number of organ and tissue transplantation procedures worldwide. HLA typing plays a crucial role in identifying compatible donors and reducing the risk of transplant rejection. Hospitals and transplant centers extensively use diagnostic HLA testing to ensure accurate donor-recipient matching. Rising prevalence of chronic diseases such as kidney failure and leukemia is increasing the demand for transplant procedures. Additionally, advancements in molecular diagnostic technologies are improving testing precision and clinical outcomes. Government initiatives promoting organ donation and transplantation awareness are also contributing to the growth of this segment. The expansion of transplant registries and improved healthcare infrastructure are further supporting the adoption of diagnostic HLA typing services globally.

The Research segment is expected to witness the fastest CAGR of 10.4% from 2026 to 2033, fueled by the growing focus on immunogenetics and transplant immunology research. Academic institutions and biotechnology companies are increasingly conducting studies to understand genetic compatibility and immune responses in transplantation. Research activities involving next-generation sequencing and bioinformatics are expanding the application scope of HLA typing technologies. Rising investments in genomics research and personalized medicine are further driving demand in this segment. Collaborative research programs between universities and pharmaceutical companies are also supporting innovation in transplant diagnostics. Additionally, increasing government funding for biomedical research is accelerating the adoption of HLA typing technologies in research settings.

• By End-use

On the basis of end-use, the market is segmented into Hospitals and Academic and Research Institutes. The Hospitals segment dominated the largest market revenue share of 54.8% in 2025, driven by the growing number of transplant surgeries performed in hospital settings. Hospitals serve as primary centers for organ transplantation and therefore require advanced HLA typing diagnostics to ensure successful donor-recipient matching. The presence of specialized transplant units and skilled healthcare professionals further supports the adoption of HLA typing services. Increasing patient admissions related to chronic organ failure are also boosting testing demand. Hospitals are continuously investing in advanced molecular diagnostic technologies to improve transplant success rates. Additionally, expanding healthcare infrastructure and government support for transplant programs are contributing to segment growth.

The Academic and Research Institutes segment is expected to witness the fastest CAGR of 10.9% from 2026 to 2033, driven by increasing research activities in immunology, genomics, and transplantation science. Research institutes play a critical role in developing innovative HLA typing technologies and improving donor matching techniques. Growing collaborations between universities, biotechnology companies, and healthcare organizations are accelerating research advancements. Additionally, rising funding for genetic research and personalized medicine is expanding the use of HLA typing in academic laboratories. Increasing participation in international transplant registries and genetic databases is further supporting segment growth.

U.S. Human Leukocyte Antigen (HLA) Typing Transplant Diagnostics Services Market Share

The Human Leukocyte Antigen (HLA) Typing Transplant Diagnostics Services industry is primarily led by well-established companies, including:

• Thermo Fisher Scientific Inc. (U.S.)
• Illumina, Inc. (U.S.)
• QIAGEN N.V. (Netherlands)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• CareDx, Inc. (U.S.)
• Omixon Biocomputing Ltd. (Hungary)
• GenDx (Netherlands)
• Luminex Corporation (U.S.)
• Bio-Rad Laboratories, Inc. (U.S.)
• Becton, Dickinson and Company (U.S.)
• Immucor, Inc. (U.S.)
• Histogenetics LLC (U.S.)
• Biofortuna Ltd. (U.K.)
• One Lambda (U.S.)
• TBG Diagnostics Limited (Australia)
• HLA Diagnostics, Inc. (U.S.)
• Bag Healthcare GmbH (Germany)
• Abbott (U.S.)
• Eurofins Scientific (Luxembourg)
• Stemcell Technologies (Canada)

Latest Developments in U.S. Human Leukocyte Antigen (HLA) Typing Transplant Diagnostics Services Market

• In March 2022, Immucor, Inc., a provider of transfusion and transplant diagnostics solutions, announced the launch of MIA FORA NGS Express HLA Typing Software, designed to improve the accuracy and speed of human leukocyte antigen typing workflows. The software enhances next-generation sequencing (NGS) data analysis and enables laboratories to obtain high-resolution donor-recipient matching results more efficiently for transplant diagnostics
• In November 2022, Illumina, Inc., a global leader in genomic sequencing technologies, announced the opening of a new Illumina Solutions Center in Dubai, aimed at expanding genomic research capabilities and strengthening access to advanced sequencing technologies, including HLA typing applications used in transplant diagnostics and immunogenetics research
• In September 2023, Omixon, Inc., a specialized provider of HLA typing solutions, launched the NanoTYPE RUO Multiplex Human Leukocyte Antigen Amplification Kit, compatible with Oxford Nanopore’s MinION sequencing platform. The kit enhances the efficiency and speed of high-resolution HLA typing workflows, supporting improved donor-recipient matching for organ and stem cell transplantation
• In February 2024, Luminex Corporation introduced the xMAP INTELLIFLEX system with enhanced HLA typing capabilities, featuring automated sample processing and multiplexing technologies that improve laboratory efficiency and reduce turnaround time for transplant compatibility testing
• In June 2024, QIAGEN launched the QIAseq HLA Typing Panel v2, designed with expanded allele coverage and improved sequencing resolution to support accurate compatibility assessment for both solid organ and hematopoietic stem cell transplantation. The innovation strengthens high-resolution HLA genotyping capabilities for clinical and research laboratories
• In October 2024, CareDx, Inc. announced advancements in its AlloSeq and QTYPE HLA typing solutions, including enhanced single-bead antigen resolution to support virtual crossmatching in deceased donor typing, enabling transplant centers to make faster and more accurate donor-recipient compatibility decisions
• In April 2025, Thermo Fisher Scientific launched the One Lambda HybriType HLA Plus Typing Flex Kit, a next-generation sequencing-based assay designed to streamline HLA typing workflows and reduce total processing time to under 5.5 hours. The solution improves genotyping accuracy and laboratory efficiency for transplant diagnostics applications
• In October 2025, CareDx, Inc. introduced AlloSeq Tx11, a next-generation HLA typing solution with enhanced Class II coverage designed to improve donor-recipient matching for solid organ and hematopoietic stem cell transplantation, supporting more precise transplant diagnostics services

SKU-18152